Istradefylline OK'd for Parkinson, RimabotulinumtoxinB Approved for Chronic Sialorrhea, Dementia in Chronic Truamatic Encephalopathy
Neurology News Network for the week ending August 31, 2019.
This week, Neurology News Network covered the FDA approval of Kyowa Kirin’s istradefylline for the use as an add-on therapy to levodopa/carbidopa in the treatment of Parkinson disease, as well as the agency’s approval of rimabotulinumtoxinB (Myobloc, US WorldMeds) for the treatment of chronic sialorrhea. Additionally, the network covered the findings of a recent trial of the pathway of dementia in those with chronic traumatic encephalopathy (transcript below).
Matt:
Welcome to Neurology News Network. I’m Matt Hoffman. Let’s get into the news from this week.
The FDA has given the
The FDA also approved a
Recent study findings suggest that in
For more direct access to expert insight, head to neurologylive.com. This has been Neurology News Network. Thanks for watching.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.